Guggenheim analyst Seamus Fernandez raised the firm’s price target on Amylyx (AMLX) to $30 from $25 and keeps a Buy rating on the shares based on “high confidence” in a positive LUCIDITY readout with topline data confirmed to be coming in Q3. Data from LUCIDITY could establish avexitide as the first-ever FDA approved treatment for 150,000-plus postbariatric hypoglycemia patients in the U.S., the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
- Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
- Amylyx price target raised to $34 from $28 at H.C. Wainwright
- Amylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating
- Amylyx files automatic mixed securities shelf